A Cdk7 inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

YKL-5-124

Item No. 31057

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-[(1S)-2-(dimethylamino)-1-phenylethyl]-4,6-dihydro-6,6-dimethyl-3-[[4-[(1-oxo-2-propen-1-yl)amino]benzoyl]amino]-pyrrolo[3,4-c]pyrazole-5(1H)-carboxamide
CAS Number
1957203-01-8
Molecular Formula
C28H33N7O3
Formula Weight
515.6
Purity
≥90%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Sparingly soluble: 1-10 mg/mlEthanol: Slightly soluble: 0.1-1 mg/ml
SMILES
O=C(N[C@H](CN(C)C)C1=CC=CC=C1)N2C(C)(C)C(NN=C3NC(C4=CC=C(NC(C=C)=O)C=C4)=O)=C3C2
InChi Code
InChI=1S/C28H33N7O3/c1-6-23(36)29-20-14-12-19(13-15-20)26(37)31-25-21-16-35(28(2,3)24(21)32-33-25)27(38)30-22(17-34(4)5)18-10-8-7-9-11-18/h6-15,22H,1,16-17H2,2-5H3,(H,29,36)(H,30,38)(H2,31,32,33,37)/t22-/m1/s1
InChi Key
KPABJHHKKJIDGX-JOCHJYFZSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $28

    Add

    5 mg

    $117

    Add

    10 mg

    $220

    Add

    25 mg

    $516

    Add
    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    YKL-5-124 is an inhibitor of cyclin-dependent kinase 7 (Cdk7; IC50 = 9.7 nM).1 It is selective for Cdk7 over Cdk2 and Cdk9 (IC50s = 1,300 and 3,020 nM, respectively). YKL-5-124 (60 nM) induces cell cycle arrest at G1 and G2 phases in HAP1 chronic myeloid leukemia (CML) cells. It also inhibits HIV-1 provirus expression in HIV-1 infected J-Lat 10.6 T cell acute lymphoblastic leukemia cells when used at a concentration of 100 nM.2 In vivo, YKL-5-124 (2.5 mg/kg per day), in combination with (+)-JQ1 (Item No. 11187), decreases tumor volume and increases survival in a patient-derived xenograft (PDX) mouse model of neuroblastoma.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Olson, C.M., Liang, Y., Leggett, A., et al. Development of a selective CDK7 covalent inhibitor reveals predominant cell-cycle phenotype. Cell Chem. Biol. 26(6), 792-803.e710 (2019).

    2. Horvath, R.M., Brumme, Z.L., and Sadowski, I. Small molecule inhibitors of transcriptional cyclin-dependent kinases impose HIV-1 latency, presenting "block and lock" treatment strategies. Antimicrob. Agents Chemother. 68(3), e0107223 (2024).

    3. Gao, Y., Volegova, M., Nasholm, N., et al. Synergistic anti-tumor effect of combining selective CDK7 and BRD4 inhibition in neuroblastoma. Front. Oncol. 11, 773186 (2022).